Seven IPOs raising at least $100 million are currently scheduled for the week ahead, in what could be one of the busiest weeks for sizable offerings since 2021. Notably, only one other week over the past four years has produced seven $100 million-plus IPOs,...read more
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, announced terms for its IPO on Wednesday. The New Haven, CT-based company plans to raise $200 million by offering 13.4 million shares at a price range of $14 to $16. At the midpoint of...read more
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Veradermics Therapeutics is a dermatologist-founded, late clinical-stage biopharmaceutical company ...read more
US IPO Week Ahead: At least 7 sizable IPOs teed up in one of the busiest weeks in four years
Seven IPOs raising at least $100 million are currently scheduled for the week ahead, in what could be one of the busiest weeks for sizable offerings since 2021. Notably, only one other week over the past four years has produced seven $100 million-plus IPOs,...read more
Hair loss biotech Veradermics sets terms for $200 million IPO
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, announced terms for its IPO on Wednesday. The New Haven, CT-based company plans to raise $200 million by offering 13.4 million shares at a price range of $14 to $16. At the midpoint of...read more
US IPO Weekly Recap: Aktis Oncology leads as first sizable 2026 IPO
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Hair loss biotech Veradermics files for a $100 million IPO
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Veradermics Therapeutics is a dermatologist-founded, late clinical-stage biopharmaceutical company ...read more